
OPRX
USDOptimizeRx Corporation Common Stock
السعر في الوقت الحقيقي
مخطط الأسعار
المقاييس الرئيسية
مقاييس السوق
الافتتاح
$18.900
الأعلى
$19.383
الأدنى
$18.689
الحجم
0.42M
أساسيات الشركة
القيمة السوقية
356.4M
الصناعة
Health Information Services
البلد
United States
إحصاءات التداول
متوسط الحجم
0.37M
البورصة
NCM
العملة
USD
نطاق 52 أسبوعاً
تقرير تحليل الذكاء الاصطناعي
آخر تحديث: ٣٠ أكتوبر ٢٠٢٥OPRX Analysis: Navigating OptimizeRx's Volatile Growth Path
Recent Price Movements
- July-August Transition: Shares jumped 37% on August 8 (12.84→17.30) with volume 5x average
- September Rally: Steady climb from 17.16 (Sept 2) to 20.51 (Sept 29) - 19.5% gain
- Current Position: Trading at $20.56 (Oct 29) after hitting $22.25 weekly high
- Pattern Alert: 3 failed attempts to hold above $22 since late September
Key Catalysts
- October 10 Analyst Boost: JMP Securities raised target to $23 (+15% from current)
- AI Prediction Signals:
- Short-term projections: +1.1% (D1), +1.7% (D2), +2.5% (D3)
- High-confidence bullish signal (81.1% AI confidence)
- Volume Surges: 3 recent spikes (584k on Aug 28, 662k on Sept 29, 421k on Oct 24)
Strategic Considerations
Strengths
- Explosive revenue growth (55.2% YoY)
- Strong institutional interest (4.9x average volume days)
- Healthcare tech positioning in growing sector
Concerns
- Profitability challenges (Negative ROE: -8.2%)
- Heavy debt load (24.29 Debt/Equity ratio)
- Technical resistance at $22 level
Actionable Insights
- Entry Window: Current price ($20.56) near support level ($20.55)
- Trade Parameters:
- Stop Loss: $18.48 (10% downside protection)
- Take Profit: $22.50 (9.4% upside)
- Alternative Entries: $20.64-$21.08 range
- Holding Strategy: 1-2 week horizon aligns with AI predictions
Final Perspective
OptimizeRx presents a high-growth opportunity tempered by financial health concerns. The combination of analyst upgrades, AI bullishness, and technical support near current levels creates a favorable risk/reward scenario for short-term traders. Long-term investors should monitor debt management and profitability improvements.
Disclaimer: This analysis references historical data and AI predictions that may not reflect future performance. Consult a financial advisor before making investment decisions. Past performance does not guarantee future results.
أخبار ذات صلة
JMP Securities Maintains Market Outperform on OptimizeRx, Raises Price Target to $23
JMP Securities analyst Constantine Davides maintains OptimizeRx with a Market Outperform and raises the price target from $20 to $23.
تنبؤ الذكاء الاصطناعيBeta
توصية الذكاء الاصطناعي
تم التحديث في: ٤ نوفمبر ٢٠٢٥، ٠٥:٠٩ م
65.0% الثقة
المخاطر والتداول
نقطة الدخول
$19.62
جني الأرباح
$20.97
وقف الخسارة
$17.52
العوامل الرئيسية
أسهم ذات صلة
ابق على اطلاع
تعيين تنبيهات الأسعار، الحصول على تحديثات تحليل الذكاء الاصطناعي وأخبار السوق في الوقت الحقيقي.